Vertex's Orkambi points to more effective CF therapies
This article was originally published in Scrip
The development of Vertex's fixed-dose combination for cystic fibrosis Orkambi (ivacaftor plus lumacaftor) should provide some benefit to patients with the most common mutation associated with the disease but really just paves the way for more effective treatments, experts say.
You may also be interested in...
The leading PARP inhibitor gets a new tumor type added to its label after a narrow ODAC vote in favor less than a fortnight ago.
Andrew McConaghie and Alex Shimmings are joined by John Hawkins, biographer of biotech pioneer Henri Termeer, and Idea Pharma's Mike Rea to pick out their personal book highlights of 2019.
Concerns that written interventions might delay the expected EU approval of the novel ketamine-based antidepressant have come to naught.